NCT00089908View on ClinicalTrials.gov

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Dengue Fever
Interventions
BIOLOGICAL

rDEN1delta30

Live attenuated rDEN1delta30 vaccine

BIOLOGICAL

Placebo

Placebo for rDEN1delta30

Trial Locations (1)

21205

Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00089908 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults | Biotech Hunter | Biotech Hunter